Abbott’s Whole Blood Rapid Test Gains the US FDA’s Clearance to Evaluate Concussion
Shots:
- The US FDA has cleared the company’s i-STAT TBI cartridge for its use with whole blood enabling evaluation of patients with suspected concussion to obtain outcomes within 15mins.
- The test can assess patients aged 18yrs. and above with suspected concussion up to 24 hours after injury at the patient’s bedside, extending availability to urgent care and other healthcare settings
- The i-STAT TBI cartridge, used with the i-STAT Alinity System, requires a small venous blood sample to measure two brain biomarkers, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), enabling the assessment of potential brain injury for treatment decisions
Ref: Abbott | Image: Abbott
Related News:- Abbott Reports Data from the Real-World Studies of Freestyle Libre Systems and GLP-1 Therapy in Patients with Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
